{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:51:57Z","timestamp":1787320317743,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T00:00:00Z","timestamp":1329436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s11060-012-0804-9","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T14:44:06Z","timestamp":1329403446000},"page":"53-58","source":"Crossref","is-referenced-by-count":6,"title":["Systemic rapamycin alone may not be a treatment option for malignant glioma: evidence from an in vivo study"],"prefix":"10.1007","volume":"108","author":[{"given":"Marina","family":"Mendiburu-Eli\u00e7abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dali","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Hadaczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Forsayeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystof S.","family":"Bankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,17]]},"reference":[{"key":"804_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1998.88.1.0001","volume":"88","author":"FG Davis","year":"1998","unstructured":"Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973\u20131991. J Neurosurg 88:1\u201310","journal-title":"J Neurosurg"},{"key":"804_CR2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","volume":"344","author":"LM DeAngelis","year":"2001","unstructured":"DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114\u2013123","journal-title":"N Engl J Med"},{"key":"804_CR3","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1073\/pnas.97.12.6242","volume":"97","author":"EC Holland","year":"2000","unstructured":"Holland EC (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 97:6242\u20136244","journal-title":"Proc Natl Acad Sci USA"},{"key":"804_CR4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/07357909609076900","volume":"14","author":"AA Brandes","year":"1996","unstructured":"Brandes AA, Fiorentino MV (1996) The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 14:551\u2013559","journal-title":"Cancer Invest"},{"key":"804_CR5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/cncr.20073","volume":"100","author":"P Hau","year":"2004","unstructured":"Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hubner F, Jauch T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahn U (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100:1199\u20131207","journal-title":"Cancer"},{"key":"804_CR6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1471-4914(01)02161-X","volume":"7","author":"PK Vogt","year":"2001","unstructured":"Vogt PK (2001) PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 7:482\u2013484","journal-title":"Trends Mol Med"},{"key":"804_CR7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0962-8924(02)00042-9","volume":"13","author":"S Oldham","year":"2003","unstructured":"Oldham S, Hafen E (2003) Insulin\/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol 13:79\u201385","journal-title":"Trends Cell Biol"},{"key":"804_CR8","first-page":"3504","volume":"60","author":"A Sekulic","year":"2000","unstructured":"Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504\u20133513","journal-title":"Cancer Res"},{"key":"804_CR9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489\u2013501. doi: 10.1038\/nrc839nrc839","journal-title":"Nat Rev Cancer"},{"key":"804_CR10","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.onc.1209992","volume":"26","author":"A Iwamaru","year":"2007","unstructured":"Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB, Kondo S (2007) Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26:1840\u20131851. doi: 10.10138\/sj.onc.1209992","journal-title":"Oncogene"},{"key":"804_CR11","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2004.07.193","volume":"22","author":"A Chakravarti","year":"2004","unstructured":"Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926\u20131933. doi: 10.1200\/JCO.2004.07.193","journal-title":"J Clin Oncol"},{"key":"804_CR12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1215\/15228517-4-3-196","volume":"4","author":"CB Knobbe","year":"2002","unstructured":"Knobbe CB, Merlo A, Reifenberger G (2002) Pten signaling in gliomas. Neuro Oncol 4:196\u2013211","journal-title":"Neuro Oncol"},{"key":"804_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1215\/S1152851704000420","volume":"7","author":"AB Heimberger","year":"2005","unstructured":"Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF (2005) Mechanisms of action of rapamycin in gliomas. Neuro Oncol 7:1\u201311. doi: 10.1215\/S1152851704000420","journal-title":"Neuro Oncol"},{"key":"804_CR14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00685908","volume":"33","author":"JG Supko","year":"1994","unstructured":"Supko JG, Malspeis L (1994) Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. Cancer Chemother Pharmacol 33:325\u2013330","journal-title":"Cancer Chemother Pharmacol"},{"key":"804_CR15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","volume":"23","author":"SM Chang","year":"2005","unstructured":"Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357\u2013361. doi: 10.1007\/s10637-005-1444-0","journal-title":"Invest New Drugs"},{"key":"804_CR16","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294\u20135304","journal-title":"J Clin Oncol"},{"key":"804_CR17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/jcbfm.1994.108","volume":"14","author":"T Inamura","year":"1994","unstructured":"Inamura T, Black KL (1994) Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 14:862\u2013870. doi: 10.1038\/jcbfm.1994.108","journal-title":"J Cereb Blood Flow Metab"},{"key":"804_CR18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.brainres.2008.06.122","volume":"1230","author":"KL Black","year":"2008","unstructured":"Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, Ko MK, Bayan JA, Sacapano MR, Espinoza A, Irvin DK, Shu Y (2008) PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 1230:290\u2013302. doi: 10.1016\/j.brainres.2008.06.122","journal-title":"Brain Res"},{"key":"804_CR19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/2.1.45","volume":"2","author":"DR Groothuis","year":"2000","unstructured":"Groothuis DR (2000) The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2:45\u201359","journal-title":"Neuro Oncol"},{"key":"804_CR20","first-page":"8451","volume":"63","author":"AL Edinger","year":"2003","unstructured":"Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63:8451\u20138460","journal-title":"Cancer Res"},{"key":"804_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","volume":"10","author":"R Loewith","year":"2002","unstructured":"Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457\u2013468","journal-title":"Mol Cell"},{"key":"804_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0968-0004(00)89056-8","volume":"20","author":"M Ui","year":"1995","unstructured":"Ui M, Okada T, Hazeki K, Hazeki O (1995) Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem Sci 20:303\u2013307","journal-title":"Trends Biochem Sci"},{"key":"804_CR23","doi-asserted-by":"crossref","unstructured":"Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc Natl Acad Sci U S A 98: 10314-10319 doi: 10.1073\/pnas.171076798","DOI":"10.1073\/pnas.171076798"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0804-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-012-0804-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0804-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T16:54:20Z","timestamp":1561308860000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-012-0804-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s11060-012-0804-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,17]]}}}